LOS ANGELES--(BUSINESS WIRE)--The Schall Law Firm, a national shareholder rights litigation firm, reminds investors of a class action lawsuit against Ginkgo Bioworks Holdings, Inc. f/k/a Soaring Eagle Acquisition Corp. (“Ginkgo” or “the Company”) (NYSE: DNA, NASDAQ: SRNG) for violations of §§10(b) and 20(a) of the Securities Exchange Act of 1934 and Rule 10b-5 promulgated thereunder by the U.S. Securities and Exchange Commission.
Investors who purchased the Company's securities between May 11, 2021 and October 5, 2021, inclusive (the ''Class Period''), are encouraged to contact the firm before January 17, 2022.
If you are a shareholder who suffered a loss, click here to participate.
We also encourage you to contact Brian Schall of the Schall Law Firm, 2049 Century Park East, Suite 2460, Los Angeles, CA 90067, at 310-301-3335, to discuss your rights free of charge. You can also reach us through the firm's website at www.schallfirm.com, or by email at firstname.lastname@example.org.
The class, in this case, has not yet been certified, and until certification occurs, you are not represented by an attorney. If you choose to take no action, you can remain an absent class member.
According to the Complaint, the Company made false and misleading statements to the market. Ginkgo was almost completely dependent on related parties due to its failure to earn significant revenues from third-party customers. The Company derived most or all of its revenue from related parties it created or otherwise controlled. The Company concealed its dependence on related parties by misclassifying and underreporting related party revenues. Many of the Company’s new R&D partners were undisclosed related parties. Based on these facts, the Company’s public statements were false and materially misleading. When the market learned the truth about Ginkgo, investors suffered damages.
Join the case to recover your losses.
The Schall Law Firm represents investors around the world and specializes in securities class action lawsuits and shareholder rights litigation.
This press release may be considered Attorney Advertising in some jurisdictions under the applicable law and rules of ethics.